Why Moderna (MRNA) Stock Is Down Today

Moderna (MRNA) is down 4.2% today. Here is some analysis on what might have caused this price movement.

Analysis: A clear negative company-specific announcement is not obvious today, so the pullback appears most likely to be a round of profit-taking after Moderna’s recent surge. This could be because investors are locking in gains after last week’s earnings beat and guidance increase, while reassessing whether the recent rally already priced in much of the good news.

Details:

Moderna reported third-quarter 2026 results on November 6 that showed revenue of about $1.3 billion and diluted earnings per share of $0.38, a swing back to profitability from the prior year.

The company also raised its 2026 revenue growth outlook to 15% to 25% and lifted its expected year-end cash balance to roughly $8.1 billion to $8.3 billion.

Shares had already moved sharply higher around the earnings release, so a decline today fits a pattern of investors trimming positions after a fast run-up rather than reacting to a fresh setback.

Analyst sentiment still looks mixed even after recent target increases, which may be limiting follow-through buying at elevated levels.

Sources:

SEC, Moderna Investor Relations, Yahoo Finance

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$MRNA Insider Trading Activity

$MRNA insiders have traded $MRNA stock on the open market 17 times in the past 6 months. Of those trades, 0 have been purchases and 17 have been sales.

Here’s a breakdown of recent trading of $MRNA stock by insiders over the last 6 months:

STEPHEN HOGE (President) has made 0 purchases and 8 sales selling 318,952 shares for an estimated $37,631,803.
STEPHANE BANCEL (Chief Executive Officer) has made 0 purchases and 4 sales selling 499,246 shares for an estimated $28,715,011.
JAMES M MOCK (Chief Financial Officer) has made 0 purchases and 2 sales selling 34,836 shares for an estimated $4,685,093.
SHANNON THYME KLINGER (Chief Legal Officer) has made 0 purchases and 2 sales selling 6,942 shares for an estimated $659,316.
NOUBAR AFEYAN sold 9,263 shares for an estimated $433,878

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$MRNA Hedge Fund Activity

We have seen 549 institutional investors add shares of $MRNA stock to their portfolio, and 359 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

FMR LLC added 7,096,057 shares (+13.7%) to their portfolio in Q3 2026, for an estimated $1,366,487,696
BAILLIE GIFFORD & CO removed 6,768,791 shares (-37.2%) from their portfolio in Q3 2026, for an estimated $1,303,466,082
D. E. SHAW & CO., INC. removed 5,157,808 shares (-99.5%) from their portfolio in Q2 2026, for an estimated $361,201,294
PRICE T ROWE ASSOCIATES INC /MD/ added 4,850,982 shares (+656.8%) to their portfolio in Q2 2026, for an estimated $339,714,269
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 4,838,884 shares (+inf%) to their portfolio in Q2 2026, for an estimated $338,867,046
CAPITAL WORLD INVESTORS added 3,579,302 shares (+19.1%) to their portfolio in Q2 2026, for an estimated $250,658,519
ALYESKA INVESTMENT GROUP, L.P. removed 3,490,366 shares (-86.2%) from their portfolio in Q2 2026, for an estimated $244,430,330

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$MRNA Congressional Stock Trading

Members of Congress have traded $MRNA stock 3 times in the past 6 months. Of those trades, 1 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $MRNA stock by members of Congress over the last 6 months:

REPRESENTATIVE MARIA ELVIRA SALAZAR has traded it 3 times. They made 1 purchase worth up to $15,000 on 08/19 and 2 sales worth up to $30,000 on 09/24, 08/19.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$MRNA Price Targets

Multiple analysts have issued price targets for $MRNA recently. We have seen 4 analysts offer price targets for $MRNA in the last 6 months, with a median target of $42.0.

Here are some recent targets:

Matthew Harrison from Morgan Stanley set a target price of $39.0 on 07/08/2026
Luca Issi from RBC Capital set a target price of $45.0 on 07/07/2026
Dimple Gosai from B of A Securities set a target price of $38.0 on 07/07/2026
Edward Tenthoff from Piper Sandler set a target price of $77.0 on 06/26/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.